Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313) Meeting Abstract
| Authors: | Choueiri, T. K.; Powles, T. B.; Albiges, L.; Burotto, M.; Szczylik, C.; Zurawski, B.; Riuz, E. Y.; Maruzzo, M.; Zaizar, A. S.; Fein, L. E.; Schutz, F. A. B.; Heng, D. Y. C.; Wang, F.; Mataveli, F.; Chang, Y. L.; van Kooten Losio, M.; Rodriguez, C. S.; Motzer, R. J. |
| Abstract Title: | Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313) |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | 2022 Sep 9-13 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S1430 |
| End Page: | S1431 |
| Language: | English |
| ACCESSION: | WOS:000866211602480 |
| DOI: | 10.1016/j.annonc.2022.08.070 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA8 -- Source: Wos |
